| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/23744235.2016.1247495 |
| P698 | PubMed publication ID | 27804313 |
| P50 | author | Anders Blaxhult | Q98956811 |
| Lars Naver | Q42816822 | ||
| Jan Albert | Q39183357 | ||
| P2093 | author name string | Anders Sönnerborg | |
| Magnus Gisslén | |||
| Leo Flamholc | |||
| Jaran Eriksen | |||
| Veronica Svedhem | |||
| Olof Karlström | |||
| Aylin Yilmaz | |||
| Christina Carlander | |||
| Filip Josephson | |||
| P2860 | cites work | Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution. | Q50976272 |
| Immune control of HIV-1 after early treatment of acute infection | Q56961920 | ||
| Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China | Q58299231 | ||
| Current CD4 Cell Count and the Short‐Term Risk of AIDS and Death before the Availability of Effective Antiretroviral Therapy in HIV‐Infected Children and Adults | Q59119626 | ||
| Prevention of HIV-1 infection with early antiretroviral therapy | Q24634688 | ||
| Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment | Q24803596 | ||
| Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic review | Q26829541 | ||
| Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review | Q26851448 | ||
| Minority drug-resistant HIV-1 variants in treatment naïve East-African and Caucasian patients detected by allele-specific real-time PCR | Q28543986 | ||
| Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral Therapy | Q28547869 | ||
| CD4+ count-guided interruption of antiretroviral treatment | Q29619489 | ||
| Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r | Q31051809 | ||
| Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). | Q33372615 | ||
| Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women | Q33638545 | ||
| Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue | Q33769993 | ||
| Effect of early versus deferred antiretroviral therapy for HIV on survival | Q33789114 | ||
| When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study | Q33876261 | ||
| Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin | Q33983600 | ||
| Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study | Q34011661 | ||
| Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). | Q34012918 | ||
| Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis | Q34024416 | ||
| Short-course antiretroviral therapy in primary HIV infection | Q34037516 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| Early Antiretroviral Therapy and Mortality among HIV-Infected Infants | Q34175450 | ||
| No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial | Q34220902 | ||
| Risk of HIV transmission from patients on antiretroviral therapy: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy | Q34336508 | ||
| Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy | Q34340792 | ||
| Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial | Q34373867 | ||
| Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study | Q34413527 | ||
| A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team | Q34438252 | ||
| On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection | Q34503668 | ||
| HLA-B*5701 screening for hypersensitivity to abacavir | Q34747145 | ||
| Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study | Q34756398 | ||
| Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors? | Q34854631 | ||
| Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection | Q39570904 | ||
| Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results | Q39599742 | ||
| Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines | Q39707218 | ||
| HIV-1 low copy viral sequencing-A prototype assay | Q40111552 | ||
| Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy | Q40646587 | ||
| Transition of HIV-infected youths from paediatric to adult care, a Swedish single-centre experience | Q40764970 | ||
| Deficiencies in the health care system contribute to a high rate of late HIV diagnosis in Sweden | Q40913298 | ||
| Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials | Q41044551 | ||
| Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. | Q42198414 | ||
| Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients | Q42205529 | ||
| Early highly active antiretroviral therapy enhances B-cell longevity: a 5 year follow up. | Q42234700 | ||
| Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. | Q42260844 | ||
| A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resul | Q42275853 | ||
| Impact of timing of antiretroviral therapy initiation on survival of cervical squamous intraepithelial lesions: a cohort analysis from South Africa. | Q42281911 | ||
| Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. | Q42671235 | ||
| An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe | Q43106626 | ||
| Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial | Q43259468 | ||
| Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial | Q43300648 | ||
| Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. | Q43451461 | ||
| A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 r | Q43708339 | ||
| Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir | Q43807080 | ||
| Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections | Q43851688 | ||
| Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. | Q44043469 | ||
| Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. | Q44129942 | ||
| British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010. | Q44214722 | ||
| Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects | Q44289523 | ||
| Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine | Q45016493 | ||
| Human papillomavirus infection in women infected with the human immunodeficiency virus | Q45759660 | ||
| Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus | Q45765734 | ||
| A high occurrence of late presenters and missed HIV diagnosis in clinical care in Sweden | Q46179384 | ||
| Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. | Q46738531 | ||
| Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis | Q47372780 | ||
| Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women | Q35008398 | ||
| Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients | Q35019859 | ||
| Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents | Q35072975 | ||
| Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters | Q35231130 | ||
| The known unknowns of HPV natural history | Q35578583 | ||
| The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals | Q35623734 | ||
| Effect of Age at Antiretroviral Therapy Initiation on Catch-up Growth Within the First 24 Months Among HIV-infected Children in the IeDEA West African Pediatric Cohort | Q35738443 | ||
| Updated research nosology for HIV-associated neurocognitive disorders | Q35755761 | ||
| Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers | Q35802558 | ||
| Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts | Q35815274 | ||
| Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis | Q35887051 | ||
| Cervical Precancer Risk in HIV-Infected Women Who Test Positive for Oncogenic Human Papillomavirus Despite a Normal Pap Test | Q36187634 | ||
| Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies | Q36285986 | ||
| Influence of HIV co-infection on hepatitis C immunopathogenesis | Q36336132 | ||
| Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions | Q36342389 | ||
| Highly active antiretroviral therapy and cervical dysplasia in HIV-positive women in South Africa | Q36404058 | ||
| Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial | Q36426896 | ||
| Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection | Q36567658 | ||
| Human papillomavirus vaccination in HIV-infected women: need for increased coverage | Q36780952 | ||
| Early versus standard antiretroviral therapy for HIV-infected adults in Haiti | Q36914021 | ||
| The European preexposure prophylaxis revolution | Q36956187 | ||
| Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children. | Q37108384 | ||
| Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial | Q37189075 | ||
| Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant | Q37356747 | ||
| Class-sparing regimens for initial treatment of HIV-1 infection | Q37454026 | ||
| European guidelines on the clinical management of HIV-1 tropism testing | Q37856554 | ||
| Special aspects of the treatment of HIV-2-infected patients | Q37979706 | ||
| Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity | Q38225189 | ||
| HPV and anal cancer in HIV-infected individuals: a review | Q38225836 | ||
| Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa | Q38374183 | ||
| Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy | Q38594555 | ||
| Impact of immunosuppression and region of birth on risk of cervical intraepithelial neoplasia among migrants living with HIV in Sweden | Q38932142 | ||
| Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women | Q39144897 | ||
| P433 | issue | 1 | |
| P921 | main subject | Sweden | Q34 |
| anti-retroviral agent | Q50430310 | ||
| P304 | page(s) | 1-34 | |
| P577 | publication date | 2016-11-02 | |
| P1433 | published in | Infectious Diseases | Q7429961 |
| P1476 | title | Antiretroviral treatment for HIV infection: Swedish recommendations 2016. | |
| P478 | volume | 49 |
| Q40054177 | An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study. |
| Q38943489 | Assessing cervical intraepithelial neoplasia as an indicator disease for HIV in a low endemic setting: a population-based register study |
| Q36282702 | HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014. |
| Q36342362 | Probing Mercaptobenzamides as HIV Inactivators via Nucleocapsid Protein 7. |
| Q50054059 | Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy. |
| Q47909922 | Utility of estimated glomerular filtration rate based on cystatin C in patients receiving combination antiretroviral therapy including dolutegravir |
| Q33880782 | Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment. |
Search more.